Vanguard Asset Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Vanguard Asset Management's CORT Position: Q3 2026 in Review
Vanguard Asset Management increased its Corcept Therapeutics (CORT) stake by 6.3% in Q3 2026, buying an estimated $636K and bringing the position to 99,826 shares worth $11.5M. The position accounts for 0.01% of the portfolio, ranked #658.
Vanguard Asset Management first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 501 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Vanguard Asset Management held 99,826 shares of Corcept Therapeutics worth $11.5M as of Q3 2026.
- Vanguard Asset Management bought 5,916 Corcept Therapeutics shares in Q3 2026, an estimated $636K.
- Corcept Therapeutics made up 0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #658 holding.
- Vanguard Asset Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 501 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.